Annals of Oncology Advance Access originally published online on December 6, 2007
Annals of Oncology 2008 19(4):774-779; doi:10.1093/annonc/mdm563
hematologic malignancies |
Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome
1 Département d'Hématologie Clinique, Assistance Publique des Hôpitaux de Paris, Hôpital Saint-Louis, Institut Universitaire d'hématologie, Paris
2 Département d'Hématologie Clinique, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite
3 Université Lyon 1, Equipe d'Accueil 3737, Faculté Lyon-Sud, Oullins, France
* Correspondence to: Dr C. Thieblemont, Département d'Hémato-Oncologie (Coquelicot 6), Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France. Tel: +33-1-42-49-98-37; Fax: +33-1-42-49-96-41; E-mail: catherine.thieblemont{at}sls.aphp.fr
Background: Non-Hodgkin’s lymphoma (NHL) in patients older than 80 years is not a rare disease and treatment strategies are often difficult because of associated comorbidities.
Patients and methods: We entered 205 NHL patients older than 80 years treated in a single institution in a retrospective analysis to describe clinical presentation and outcome and to identify specific prognostic factors.
Results: The median age was 83 years, and 91% of the cases were B-cell lymphomas consisting mainly of diffuse large B-cell lymphoma and marginal zone lymphoma. Among patients presenting comorbidities (87%), Charlson index was low in almost half of the patients (43%). Patients did not receive any treatment or received corticosteroids alone in 15%, surgery, radiotherapy, or monochemotherapy in 35%, polychemotherapy without anthracycline in 18%, and anthracycline based in 32%. Median overall survival was of 2.2 years. Main reason for death was disease progression (57%). Independent prognostic factors of survival were poor performance status (P < 10–4) and high lactate dehydrogenase level (P < 10–5). Comorbidities were not found to influence survival.
Conclusions: Very elderly NHL patients showed similar features and prognostic factors than younger patients. Death was related mainly to the disease, meaning that these patients should be more frequently treated with standard treatments.
Key words: comorbities, lymphoma, prognostic factors, very elderly patients
Received for publication August 31, 2007. Revision received November 7, 2007. Accepted for publication November 12, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. R. Sperr, F. Wimazal, M. Kundi, C. Baumgartner, T. Nosslinger, A. Makrai, R. Stauder, O. Krieger, M. Pfeilstocker, and P. Valent Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group Ann. Onc., July 15, 2009; (2009) mdp258v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Errante, A. Bianco, S. M. L. Aversa, L. Salvagno, and On behalf of the Non-Hodgkin's Lymphoma Cooperativ Comment on: 'Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome' Ann. Onc., July 1, 2008; 19(7): 1359 - 1360. [Full Text] [PDF]
|
|